Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleDrug Discovery and Translational Medicine

A Novel Angiotensin-(1-7)-glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation Related Memory Dysfunction.

Meredith Hay, Robin Polt, Michael L. Heien, Todd W. Vanderah, Tally M Largen-Milnes, Kathleen E Rodgers, Torsten Falk, Mitchell J Bartlett, Kristian Doyle and John Konhilas
Journal of Pharmacology and Experimental Therapeutics February 1, 2019, jpet.118.254854; DOI: https://doi.org/10.1124/jpet.118.254854
Meredith Hay
Univ. of Arizona;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Meredith Hay
Robin Polt
Univ. of Arizona;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robin Polt
Michael L. Heien
Univ. of Arizona;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Todd W. Vanderah
Univ. of Arizona;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tally M Largen-Milnes
Univ. of Arizona.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen E Rodgers
Univ. of Arizona;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Torsten Falk
Univ. of Arizona;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mitchell J Bartlett
Univ. Arizona;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristian Doyle
Univ of Arizona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Konhilas
Univ. of Arizona;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

A growing body of evidence indicates that decreased brain blood flow, increased reactive oxygen species production (ROS), and pro-inflammatory mechanisms accelerate the progression of neurodegenerative diseases such as vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer's disease and related dementias (ADRD). There is an urgent clinical need for safe and effective therapies for the treatment and prevention of cognitive impairment known to occur in patients with VCID and chronic inflammatory diseases such as heart failure (HF), hypertension and diabetes. This study used our mouse model of VCID/HF to test our novel glycosylated Angiotensin-(1-7) peptide, PNA5, as a therapy to treat VCID and investigate circulating inflammatory biomarkers that may be involved. We demonstrate that PNA5 has greater brain penetration as compared to the native Angiotensin-(1-7) peptide. Moreover, following treatment with 1.0/mg/kg subcutaneously for 21 days, PNA5 exhibits up to 10 days of sustained cognitive protective effects in our VCID/HF mice that last beyond the peptide half-life. PNA5 reversed object recognition impairment in VCID/HF mice and rescued spatial memory impairment. PNA5 activation of MasR results in a dose-dependent inhibition of ROS in human endothelial cells. Lastly, PNA5 treatment decreased VCID/HF induced activation of brain microglia/macrophages and inhibited circulating TNF-α, IL-7 and G-CSF serum levels while increasing the anti-inflammatory cytokine IL-10. These results suggest that PNA5 is an excellent candidate and "first-in-class" therapy for treating VCID and other inflammatory related brain diseases.

  • angiotensin
  • angiotensin receptors
  • anti-inflammatory drugs
  • behavior
  • congestive heart failure
  • dementia
  • drug development
  • drug discovery
  • neuropeptides
  • neuroprotection
  • The American Society for Pharmacology and Experimental Therapeutics
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 368 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 368, Issue 3
1 Mar 2019
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Novel Angiotensin-(1-7)-glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation Related Memory Dysfunction.
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
Citation Tools
Research ArticleDrug Discovery and Translational Medicine

A Novel Angiotensin-(1-7)-glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation Related Memory Dysfunction.

Meredith Hay, Robin Polt, Michael L. Heien, Todd W. Vanderah, Tally M Largen-Milnes, Kathleen E Rodgers, Torsten Falk, Mitchell J Bartlett, Kristian Doyle and John Konhilas
Journal of Pharmacology and Experimental Therapeutics February 1, 2019, jpet.118.254854; DOI: https://doi.org/10.1124/jpet.118.254854

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleDrug Discovery and Translational Medicine

A Novel Angiotensin-(1-7)-glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation Related Memory Dysfunction.

Meredith Hay, Robin Polt, Michael L. Heien, Todd W. Vanderah, Tally M Largen-Milnes, Kathleen E Rodgers, Torsten Falk, Mitchell J Bartlett, Kristian Doyle and John Konhilas
Journal of Pharmacology and Experimental Therapeutics February 1, 2019, jpet.118.254854; DOI: https://doi.org/10.1124/jpet.118.254854
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Acetylcholine inhibits platelet activation
  • FST288-Fc Promotes Localized Growth of Skeletal Muscle
  • rhLCAT Improves Renal Dysfunction in a Mouse FLD Model
Show more Drug Discovery and Translational Medicine

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics